Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 by Sinfah Tunsarawuth for Intellectual Property Watch 17 Comments BANGKOK – Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.
New Guidelines For Tech Companies To Be Transparent, Accountable On Censoring User Content 07/05/2018 by Intellectual Property Watch 2 Comments Facebook, Google and other social media companies today were urged by groups such as the Electronic Frontier Foundation to “publicly report how many user posts they take down, provide users with detailed explanations about takedowns, and implement appeals policies to boost accountability.” The groups released a set of guidelines to address censorship.
Ukraine Eyes Patent Law Reform After Civil Society Push On Medicines Access 30/04/2018 by Dugie Standeford for Intellectual Property Watch 14 Comments Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
Patentes Sem A Realização De Análise Técnica: Uma Péssima Solução Para O Século 21 30/04/2018 by Intellectual Property Watch 2 Comments Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado.
Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 by Intellectual Property Watch 7 Comments The Brazilian government’s plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker.
USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 by William New, Intellectual Property Watch 4 Comments The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility.
USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 by William New, Intellectual Property Watch 3 Comments The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices.
How To Discover Valuable Patents 27/04/2018 by Intellectual Property Watch Leave a Comment Bastian July writes: In May 1968, the submarine USS Scorpion disappeared after a tour of duty in the North Atlantic. The initial search area was a circle twenty miles wide and thousands of feet deep. Instead of asking one or two experts for input, Navy officer John Craven assembled a large group of independent experts with a wide range of knowledge. The group included mathematicians, submarine specialists, salvage men and many others. Combining their knowledge, Craven was able to estimate the submarine’s likely location. It was found 200 yards from the group’s collective estimate. But can you also turn to the Wisdom of the Crowd when it comes to discovering the fortunes lying hidden in patents?
UK Ratifies Unified Patent Court, Moving It Closer To Reality 27/04/2018 by William New, Intellectual Property Watch 1 Comment The United Kingdom has ratified the Unified Patent Court Agreement that will allow “a single judgment in cross-border disputes between private parties over patents granted under the current intergovernmental system.” The system is administered by the European Patent Office, and the UK’s ratification leaves Germany outstanding.
USPTO Lists Changes To Post-Grant Proceedings After This Week’s SAS Decision 27/04/2018 by Intellectual Property Watch 1 Comment The United States Patent and Trademark Office has issued guidance on changes to post-grant proceedings following the 24 April decision by the US Supreme Court in the SAS Institute v Iancu case. The Court ruled that the USPTO must decide the patentability of each claim that is challenged in petitions for inter partes review.